|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ABII 10-K filed Mar 12, 2010. Financing Activities Net cash used by financing activities for the year ended December 31, 2009 included the purchase of treasury stock and cash received upon the exercise of stock options. Net cash provided by financing activities for the year ended December 31, 2008 represented cash received upon the exercise of stock options. This excerpt taken from the ABII 10-Q filed May 8, 2009. Financing Activities Net cash provided by financing activities for the three months ended March 31, 2009 represented cash received upon the exercise of stock options.
17
Table of ContentsThese excerpts taken from the ABII 10-K filed Mar 6, 2009. Financing Activities Net cash provided in financing activities was $2.4 million for the year ended December 31, 2008 compared to $752.1 million in 2007. Net cash provided from financing activities in 2008 represented cash proceeds received from the exercise of stock options. Net cash provided by financing activities in 2007 related to net transactions with Old Abraxis prior to the separation, including the $700 million in cash that was contributed to us. Net cash used in 2006 was $94.4 million which represented a net $190.0 million repayment of debt under our credit facility in connection with the 2006 Merger, partially offset by $96.5 million provided by net transactions with Old Abraxis. Financing Activities SIZE="2">Net cash provided in financing activities was $2.4 million for the year ended December 31, 2008 compared to $752.1 million in 2007. Net cash provided from financing activities in 2008 represented cash proceeds received from the We Our
46 Table of Contents
least the next twelve months. In the event we engage in future acquisitions or significant capital projects, we may have to raise additional capital through additional borrowings or the issuance of debt or equity securities. Contractual obligations
This excerpt taken from the ABII 10-Q filed Nov 14, 2008. Financing Activities Net cash provided by financing activities of $2.1 million for the nine months ended September 30, 2008 represented cash received upon the exercise of options. Net cash provided by financing activities for the nine months ended September 30, 2007 included $44.8 million in net transactions with parent company. For periods prior to November 13, 2007, net transactions with parent company were presented in lieu of stockholder’s equity as the assets and liabilities that comprised our company were a part of Old Abraxis.
19
Table of ContentsThis excerpt taken from the ABII 10-Q filed Aug 14, 2008. Financing Activities Net cash provided by financing activities for the six months ended June 30, 2008 represented cash received upon the exercise of options. Net cash provided by financing activities for the six months ended June 30, 2007 included $37.1 million in net transactions with parent company. For periods prior to November 13, 2007, net transactions with parent company were presented in lieu of stockholder’s equity as the assets and liabilities that comprised our company were a part of Old Abraxis.
19
Table of ContentsThis excerpt taken from the ABII 10-Q filed May 15, 2008. Financing Activities Net cash provided by financing activities for the three months ended March 31, 2008 represent cash received upon the exercise of options. Net cash provided in financing activities for the three months ended March 31, 2007 included $44.6 million in net transactions with parent company. For periods prior to November 13, 2007, net transactions with parent company were presented in lieu of stockholder’s equity as the assets and liabilities that comprised our company was a part of Old Abraxis. This excerpt taken from the ABII 10-K filed Mar 31, 2008. Financing Activities Net cash provided in financing activities was $752.1 million for the year ended December 31, 2007 versus a use of cash of $94.4 million in 2006. Net cash provided by financing activities in 2007 related to net transactions with Old Abraxis prior to the separation, including the $700 million in cash that was contributed to us. Net cash used in financing activities was $94.4 million in 2006, which represented a net $190.0 million repayment of debt under our credit facility in connection with the 2006 Merger, partially offset by $96.5 million provided by net transactions with Old Abraxis. Net cash provided in 2005 of $40.7 million was driven by $147.3 in net proceeds under our credit facilities, partially offset by $106.1 million of cash used in net transactions with Old Abraxis. This excerpt taken from the ABII 10-Q filed Dec 20, 2007. Financing Activities Financing activities generally included borrowings under our credit facilities, and net transactions with Abraxis BioScience. Net cash provided in financing activities was $44.8 million versus a use of cash of $128.5 million for the nine-months ended September 30, 2007 and 2006, respectively. The nine months ended September 30, 2006 included $190.0 million of repayments from borrowings under our credit facility. This excerpt taken from the ABII 8-K filed Nov 8, 2007. Financing Activities Financing activities generally included borrowings under our credit facilities, and net transactions with Abraxis BioScience. Net cash provided in financing activities was $37.1 million versus a use of cash of $161.4 million for the six-month periods ending June 30, 2007 and 2006, respectively. The six-month period in 2006 included $190.0 million of repayments from borrowings under our credit facility. Net cash used in financing activities was $94.4 million in 2006, which represented a net $190.0 million repayment of debt under our credit facility in connection with the 2006 Merger, partially offset by $127.3 million provided by net transactions with Abraxis BioScience. Net cash provided in 2005 of $40.7 million was driven by $147.3 in net proceeds under our credit facilities, partially offset by $101.5 million of cash used in net transactions with Abraxis BioScience. Net cash provided by financing activities in 2004 totaled $119.5 million, which included $109.1 million provided by net transactions with Abraxis BioScience, $7.9 million in net proceeds under our credit facility, and the $4.0 million mortgage repayment on our Elk Grove Village, Illinois facility. | EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
